Arbutus Biopharma (ABUS) Tops Q2 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. LEN
8. USO
9. LMT
10. TLT

Go back to Arbutus Biopharma (ABUS) Tops Q2 EPS by 9c

Arbutus Announces Corporate Update and Second Quarter 2017 Financial Results

August 3, 2017 4:00 PM EDT

Two New Drug Candidates Nominated for DevelopmentARB-1740 Development UpdateCompany to Host a Corporate Update Conference Call Today at 4:30 PM ET

VANCOUVER, British Columbia and WARMINSTER, Pa., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced its second quarter 2017 unaudited financial results and provided a corporate update.

Our clinical development programs are focused on HBV s-antigen (HBsAg) reduction and suppression of HBV DNA replication, which are keys to developing a curative... More